<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68857">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957540</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-16</org_study_id>
    <nct_id>NCT01957540</nct_id>
  </id_info>
  <brief_title>Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease</brief_title>
  <official_title>Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <authority>Greece: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ticagrelor administration, whose molecule resembles to adenosine, led to reduction in
      overall mortality and thrombotic cardiovascular (CV) events when directly compared to
      clopidogrel in the PLATO trial, implicating possible pleiotropic actions for the drug. It
      has been shown that ticagrelor increases adenosine concentration, by interfering with its
      red blood cells' uptake and by inducing the release of ATP which is then converted to
      adenosine. Recent studies in healthy volunteers and patients with coronary artery disease
      (CAD) have shown that ticagrelor increases the coronary blood flow in response to
      intravenous adenosine administration. Ticagrelor administration, in comparison with other
      P2Y12 inhibitors, may influence the endothelial function, as assessed by the Peripheral
      Arterial Tonometry method (EndoPAT 2000 system (Itamar Medical, Caesarea, Israel), which is
      a method for evaluating endothelial dysfunction and has been found to positively correlate
      with flow mediated dilatation (FMD).

      This is prospective, randomized study with a crossover design, which will be conducted in
      patients with CAD under prasugrel maintenance dose (MD) 10mg once a day for at least a
      3-month period. At Day 0 (day of randomization) eligible patients will be assigned to
      either:

        -  Ticagrelor 90mg twice a day for the next 15 days or

        -  Prasugrel 10mg once a day for the next 15 days At Day 0  (before treatment
           onset)patients wiil be subjected to a baseline peripheral arterial tonometry
           measurement. Measurement will be repeated at Day 15 and then treatment crossover will
           be performed for the next 15 days (without an intervening washout period). At Day 30
           patients will be subjected again to peripheral arterial tonometry assessment.
           Peripheral blood sample will be taken from the patients in Day 0 for genotyping
           control.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI) in the 2 subgroups at the end of 2 periods of treatment</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with endothelial dysfunction (RHI&lt;1.67) at the end of 2 periods of treatment</measure>
    <time_frame>15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Endothelial Function</condition>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ticagrelor 90mg bid for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 10mg od for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-74 years old

          2. Patients with stable CAD who have been submitted(?) to percutaneous intervention for
             Acute Coronary Syndrome and receiving prasugrel MD 10mg once a day for at least the
             previous 3 months.

          3. Patients giving written Informed Consent.

        Exclusion Criteria:

          1. Acute Coronary Syndrome

          2. Contraindication for administration of  prasugrel or ticagrelor

               1. Known hypersensitivity to clopidogrel or ticagrelor

               2. Active bleeding (peptic ulcer, intracranial bleeding)

               3. Severe liver impairment

               4. Any previous history of intracranial bleeding or transient ischemic attack or
                  ischemic cerebrovascular event

               5. Treatment with potent CYP3A4  inhibitors (ketoconazole, clarithromycin,
                  nefazodone, ritonavir, atazanavir)

          3. Requirement for oral anticoagulant agents prior to the day 30 visit

          4. History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal
             bleeding within the previous 3 months

          5. Increased risk for bradyarrhythmias, according to the investigator's evaluation

          6. Severe non-controlled chronic obstructive pulmonary disease

          7. Creatinine clearance &lt;30ml/min/1.73mm2

          8. HbA1c &gt; 10mg/dl
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dimitrios Alexopoulos, Professor</last_name>
    <phone>00302610999281</phone>
    <email>dalex@med.upatras.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <state>Achaia</state>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dimitrios Alexopoulos, Professor</last_name>
      <phone>00302610999281</phone>
      <email>dalex@med.upatras.gr</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Alexopoulos, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>September 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>ticagrelor</keyword>
  <keyword>prasugrel</keyword>
  <keyword>endothelial function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prasugrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
